Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 6/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.31 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.31 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11920409 | 1.00 | EPHX2 (0.39) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL11920413 | 1.00 | EPHX2 (0.39) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL557540 | 1.00 | EPHX2 (0.39) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL1676918 | 1.00 | EPHX2 (0.39) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL558796 | 1.00 | EPHX2 (0.39) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL25434198 | 1.00 | EPHX2 (0.39) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL905423 | 1.00 | EPHX2 (0.39) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL1510015 | 1.00 | EPHX2 (0.39) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL15196458 | 0.95 | EPHX2 (0.35) | EPHX2SMN1; SMN2KMT2AHDAC1HDAC2 | |
| SCHEMBL8740492 | 0.92 | STING1 (0.34) | EPHX2KMT2AALDH1A1PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-11224634-B2 | — | — | 2022-01-18 | — | — | US | disclosed |
| EP-2287184-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2011-02-23 | — | — | EP | disclosed |
| EP-2275439-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2011-01-19 | — | — | EP | disclosed |
| EP-2264065-A2 | Novel Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264066-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| US-20100009899-A1 | Novel Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-01-14 | — | — | US | disclosed |
| US-7615532-B2 | Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin | NOVO NORDISK A/S (DE) | 2009-11-10 | — | — | US | disclosed |
| EP-2107069-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2009-10-07 | — | — | EP | disclosed |
| US-20060183668-A1 | Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-1660531-A2 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005012347-A2 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | EPHX2 3868/4885SMN1; SMN2 809/4885KMT2A 3362/4885 |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | EPHX2 3125/4885SMN1; SMN2 478/4885KMT2A 2670/4885 |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | RXFP2, RXFP1, RXFP4 | EPHX2 2970/4885SMN1; SMN2 357/4885KMT2A 2556/4885 |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | EPHX2 3125/4885SMN1; SMN2 478/4885KMT2A 2670/4885 |
| US-11224634-B2 | — | RXFP2, RXFP1, RXFP4 | EPHX2 3862/4885SMN1; SMN2 368/4885KMT2A 2489/4885 |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | EPHX2 3339/4885SMN1; SMN2 587/4885KMT2A 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.